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Abstract
Introduction: Cross-regulation between TNF and type I IFN has been postulated to play an important role in 
autoimmune diseases. Therefore, we determined the effect of TNF blockade in rheumatoid arthritis (RA) on the type I 
IFN response gene activity in relation to clinical response.
Methods: Peripheral blood from 33 RA patients was collected in PAXgene tubes before and after the start of infliximab 
treatment. In a first group of 15 patients the baseline expression of type I IFN-regulated genes was determined using 
cDNA microarrays and compared to levels one month after treatment. The remaining 18 patients were studied as an 
independent group for validation using quantitative polymerase chain reaction (qPCR).
Results: Gene expression analysis revealed that anti-TNF antibody treatment induced a significant increase in type I IFN 
response gene activity in a subset of RA patients, whereas expression levels remained similar or were slightly decreased 
in others. The findings appear clinically relevant since patients with an increased IFN response gene activity after anti-
TNF therapy had a poor clinical outcome. This association was confirmed and extended for an IFN response gene set 
consisting of OAS1, LGALS3BP, Mx2, OAS2 and SERPING1 in five EULAR good and five EULAR poor responders, by qPCR.
Conclusions: Regulation of IFN response gene activity upon TNF blockade in RA is not as consistent as previously 
described, but varies between patients. The differential changes in IFN response gene activity appear relevant to the 
clinical outcome of TNF blockade in RA.
Introduction
Cytokines are key regulators of pathogenic processes in a
variety of inflammatory and autoimmune diseases. Major
roles for both tumor necrosis factor (TNF) and type I
interferon (IFN) have previously been demonstrated.
Type I IFN (IFNα/β) plays an important role in systemic
lupus erythematosus (SLE) [1]. Evidence for the role of
IFN in SLE came from the induction of disease during
IFNα/β treatment and circulating IFN inducers [2,3].
Type I IFN activity in SLE is associated with disease
severity [1]. TNF was the first cytokine convincingly
demonstrated to contribute to chronic inflammation in
several autoimmune diseases, including rheumatoid
arthritis (RA) and Crohn disease [4]. Accordingly, block-
ade of TNF activity has proven to be highly beneficial in
the treatment of these diseases [5,6].
Blockade of TNF reduces the acute-phase reaction and
decreases the local and systemic levels of inflammatory
mediators in patients with RA (reviewed in [7]). However,
the improvement varies between patients, and approxi-
mately 30% of RA patients fail to respond to this therapy.
It has been suggested that TNF suppresses IFNα produc-
tion by inhibiting both the generation of plasmacytoid
dendritic cells (pDCs) and their IFNα secretion [8,9].
Accordingly, it was shown that TNF blockade in sys-
temic-onset juvenile idiopathic arthritis (SoJIA) patients,
which resulted in a poor or fair clinical response [10]. is
associated with a higher expression of IFN response
genes [9]. The in vivo IFN bioactivity was determined by
the measurement of the expression of type I IFN response
genes in the peripheral blood cells. Similar findings were
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made for patients with primary Sjögren syndrome (SS)
who were treated with a TNF antagonist [11] in which no
evidence of efficacy of infliximab was observed [12].
Here, the type I IFN bioactivity in the blood was mea-
sured in an indirect manner, based on the use of a bioas-
say in which a serum sample is tested to induce the
expression of IFN response activity.
Since the finding of an increased IFN response gene
activity after TNF blockade was based on studies in dis-
eases in which the clinical response to therapy was shown
not to be optimal, we were interested to know whether
this effect also applied to diseases that showed a good
clinical response. Therefore, we aimed to determine the
effect of TNF blockade on the type I IFN response gene
activity in RA patients, for approximately two thirds of
whom TNF-blocking therapy is effective. Previously, we
and others demonstrated increased type I IFN response
gene activity in the peripheral blood cells of approxi-
mately 50% of anti-TNF treatment-naive RA patients
[13]. This analysis was based on the measurement of the
expression of a set of 34 type I IFN response genes.
Accordingly, others demonstrated increased levels of
IFNα in serum of a subset of RA patients [14]. Here, we
first studied whether TNF blockade in RA led to a consis-
tent increase in type I IFN response gene activity as was
reported for SoJIA and SS. Subsequently, we determined
whether anti-TNF-induced changes in IFN response
activity were associated with the clinical outcome of TNF
blockade in RA.
Materials and methods
Patients
Consecutive patients with RA according to the American
College of Rheumatology criteria were enrolled in the
study at the outpatient clinic of the Academic Medical
Center (AMC) in Amsterdam over a period of 1 year.
Inclusion criteria were 18 to 85 years of age, a failure of at
least two disease-modifying anti-rheumatic drugs
(including methotrexate [MTX]), and active disease (dis-
ease activity score using 28 joint counts [DAS28] of at
least 3.2). Patients with a history of an acute inflamma-
tory joint disease of different origin or previous use of a
TNF-blocking agent were excluded. Patients were on sta-
ble, maximally tolerable MTX treatment. Whole blood
samples (2.5 mL) were obtained using PAXgene tubes
(PreAnalytiX GmbH, Hilden, Germany) from 33 RA
patients prior to initiation of anti-TNF therapy with inf-
liximab (3 mg/kg intravenously at baseline and weeks 2
and 6 and subsequently every 8 weeks). After 4, 8, 12, and
16 weeks of treatment, another PAXgene tube was
obtained. All patients gave written informed consent, and
the study protocol was approved by the Medical Ethics
Committee (AMC). After 16 weeks of treatment, clinical
response was assessed using the European League
Against Rheumatism (EULAR) response criteria [15,16]
Table 1: Characteristics of patients at baseline
Array analysis
(n = 15)
qPCR analysis
(n = 18)
Age, years 51 (39-55) 58 (51-69)
Gender, female/male 7/8 14/4
Disease characteristics
DAS28 5.6 (4.6-7.0) 5.7 (5.0-6.6)
C-reactive protein, mg/dL 8 (6-22) 13 (5-44)
Erythrocyte sedimentation rate 25 (12-41) 32 (16-47)
ACPA titer, U/mL 100 (15-595) 541 (121-1,805)
IgM RF titer, U/mL 28 (14-133) 67 (22-182)
Disease duration, months 77 (29-240) 65 (36-1,992)
Erosions n = 13 n = 15
Medication
Methotrexate dose, mg/week 25 (20-30) 21 (15-25)
Prednisone n = 2 n = 5
NSAID n = 7 n = 12
Values are presented as median (interquartile range 25 to 75) unless indicated otherwise. ACPA, anti-citrullinated protein antibodies; DAS28, 
disease activity score using 28 joint counts; NSAID, nonsteroidal anti-inflammatory drug; qPCR, quantitative polymerase chain reaction; RF, 
rheumatoid factor.van Baarsen et al. Arthritis Research & Therapy 2010, 12:R11
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as well as the reduction in DAS28 (response defined by a
decrease in DAS28 of at least 1.2) [17]. According to the
EULAR response criteria, 6 of the 33 patients had a poor
response whereas 12 patients displayed a good response
to treatment. An overview of the patients' characteristics
is presented in Table 1.
Blood sampling for RNA isolation
Blood (2.5 mL) was drawn in PAXgene blood RNA isola-
tion tubes (PreAnalytiX GmbH) and stored at -20°C.
Tubes were thawed for 2 hours at room temperature prior
to RNA isolation. Next, total RNA was isolated using the
PAXgene RNA isolation kit according to the manufac-
turer's instructions, including a DNAse (Qiagen, Venlo,
The Netherlands) step to remove genomic DNA. Quan-
tity and purity of the RNA were tested using the Nano-
Drop spectrophotometer (NanoDrop Technologies, Inc.,
Wilmington, DE, USA).
Microarray data
In 15 patients, the baseline expression of type I IFN-regu-
lated genes was determined using cDNA microarrays and
compared with levels 1 month after treatment. Therefore,
we used 43 K cDNA microarrays (from the Stanford
Functional Genomics Facility [18]) printed on aminosi-
lane-coated slides containing approximately 20,000
unique genes. DNA spots were UV-crosslinked to the
slide using 150 to 300 mJ. Sample preparation and
microarray hybridization were performed as described
previously [13,19]. Data storage and filtering were per-
formed using the Stanford Microarray Database [20,21]
as described previously [22]. Raw data (log2) can be
downloaded from the publicly accessible Stanford data-
base website [21]. In addition, data are stored in the Gene
Expression Omnibus [23] [GEO:GSE19821].
Interferon response gene set
Previously, we showed that a prominent cluster of highly
correlated type I IFN response genes is upregulated in a
subgroup of biological-naive RA patients compared with
healthy controls [13]. A gene set consisting of 34 type I
IFN response genes was obtained from these data. A
smaller IFN gene set consisting of 15 genes was selected
for validation analysis using a BioMark™ Real-Time PCR
[Polymerase Chain Reaction] System (Fluidigm Corpora-
tion, South San Francisco, CA, USA). Detailed informa-
tion of the gene lists is presented in Table 2.
Real-time quantitative polymerase chain reaction
RNA (0.5 μg) was reverse-transcribed into cDNA using
the Revertaid H-minus cDNA synthesis kit (MBI Fer-
mentas, St. Leon-Rot, Germany) according to the manu-
facturer's instructions. Real-time quantitative PCR
(qPCR) was performed using an ABI Prism 7900HT
Sequence detection system (Applied Biosystems, Foster
City, CA, USA) using SybrGreen (Applied Biosystems).
Primers were designed using Primer Express software
and guidelines (Applied Biosystems), and used primer
sequences are listed in Additional file 1. To calculate arbi-
trary values of mRNA levels and to correct for differences
in primer efficiencies, a standard curve was constructed.
Expression levels of target genes were expressed relative
to 18SRNA.
BioMark™ Real-Time PCR System
The BioMark™ 48.48 Dynamic Array (Fluidigm Corpora-
tion) for real-time qPCR was used to simultaneously
measure the expression of 15 IFN response genes (Table
2) in 47 samples (plus one negative control) in triplicate.
The 47 samples were derived from 10 patients (five poor
and five good EULAR responders) at baseline and 1, 2, 3,
or 4 months after treatment. From two poor and one
good responder patients, the 3-month time points are
missing. This experiment was performed at the outsourc-
ing company ServiceXS (Leiden, The Netherlands). Used
pre-designed Taqman Gene Expression Assays are listed
in Additional file 1. Expression levels of target genes were
expressed relative to 18SRNA.
Statistical analysis
Data were analyzed using software programs GraphPad
Prism 4 (GraphPad Software, Inc., San Diego, CA, USA)
and SPSS version 14.0 (SPSS Inc., Chicago, IL, USA).
Data were checked for normal (Gaussian) distribution.
Paired t test analysis was used to compare pre- and post-
treatment expression levels. Two-group comparisons
were analyzed using unpaired t test or two-way analysis
of variance (ANOVA), where appropriate. Data were con-
sidered significant with P values of less than 0.05.
Results
Differential effect of tumor necrosis factor blockade on 
type I interferon signature
Previously, we compared the gene expression profiles of
p e r i p h e r a l  b l o o d  c e l l s  o f  R A  p a t i e n t s  w i t h  t h o s e  o f
healthy controls and found that a subgroup of RA
patients has an increased expression of type I IFN
response genes [13]. This increased expression in IFN
response genes was highly variable between the individ-
ual RA patients and unrelated to medication and disease
activity. In the present study, we studied the effect of TNF
blockade on the transcription of type I IFN response
genes. Therefore, we used the expression values of 34
type I IFN response genes (Table 2) (described previously
[13]), which were averaged. Subsequently, baseline values
w e r e  c o m p a r e d  w i t h  p o s t - t r e a t m e n t  l e v e l s  ( A d d i t i o n a l
file 2). At the patient group level, there was no significant
change in type I IFN response gene activity (Figure 1a).van Baarsen et al. Arthritis Research & Therapy 2010, 12:R11
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Table 2: Interferon response gene/transcript sets used in this study
IFN set
(34 genes)
Validation 
(15 genes)
Symbol NCBI mRNA accession 
number
Name
X AA075725 AA075725.1 None
X AA142842 AA142842.1 None
X AI347124 AI347124.1 None
X ATF3 NM_001030287 Activating transcription factor 3
X EIF2AK2 NM_001135651 Eukaryotic translation initiation factor 2-alpha kinase 2
X X EPSTI1 NM_001002264 Epithelial stromal interaction 1 (breast)
X Hs.128576 NM_001135993 CDNA FLJ90394 fis, clone NT2RP2005632
X Hs.97872 AI821640 Transcribed locus
X IFI16 NM_005531 Interferon, gamma-inducible protein 16
X X IFI35 NM_005533 Interferon-induced protein 35
X X IFI44L NM_006820 Interferon-induced protein 44-like
X X IFI6 NM_002038 Interferon, alpha-inducible protein 6
X X IFIT1 NM_001548 Interferon-induced protein with tetratricopeptide 
repeats 1
X IFIT2 NM_001547 Interferon-induced protein with tetratricopeptide 
repeats 2
X X IFITM1 NM_003641 Interferon-induced transmembrane protein 1 (9-27)
X IL1RN NM_000577 Interleukin 1 receptor antagonist
X X IRF2 NM_002199 Interferon regulatory factor 2
X IRF7 NM_001572 Interferon regulatory factor 7
X X ISG15 NM_005101 ISG15 ubiquitin-like modifier
X X LGALS3BP NM_005567 Lectin, galactoside-binding, soluble, 3 binding protein
X MX1 NM_001144925 Myxovirus (influenza virus) resistance 1
X X MX2 NM_002463 Myxovirus (influenza virus) resistance 2 (mouse)
X X OAS1 NM_001032409 2',5' -oligoadenylate synthetase 1, 40/46 kDa
X X OAS2 NM_001032731 2' -5' -oligoadenylate synthetase 2, 69/71 kDa
X PARP14 NM_017554 Poly (ADP-ribose) polymerase family, member 14
X PLSCR1 NM_021105 Phospholipid scramblase 1
X RNF213 NM_020914 Ring finger protein 213
X X RSAD2 NM_080657 Radical S-adenosyl methionine domain containing 2 
(alias cig5)
X RTP4 NM_022147 Receptor (chemosensory) transporter protein 4
X X SAMD9L NM_152703 Sterile alpha motif domain containing 9-like
X X SERPING1 NM_000062 Serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1
X TAP1 NM_000593 Transporter 1, ATP-binding cassette, sub-family B (MDR/
TAP)
X TNFAIP6 NM_007115 Tumor necrosis factor, alpha-induced protein 6
X UBE2L6 NM_004223 Ubiquitin-conjugating enzyme E2L 6
IFN, interferon; NCBI, National Center for Biotechnology Information.van Baarsen et al. Arthritis Research & Therapy 2010, 12:R11
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However, the regulation of IFN response genes upon
TNF blockade was highly variable between patients. The
variation was not related to gender or MTX dose or pred-
nisone or nonsteroidal anti-inflammatory drug (NSAID)
use.
To confirm these results in an independent cohort of 18
RA patients, three genes (RSAD2, IFI44L, and OAS1) that
showed the best correlation (R > 0.9) with the mean
expression value of the set of 34 type I IFN response
genes were selected. The mean expression of the three
genes was measured by real-time qPCR before and 1
month after infliximab therapy. Ten patients showed an
increased expression of these three IFN response genes
after TNF blockade, whereas in eight patients similar or
decreased levels were observed (Figure 1b). The IFN reg-
ulation was independent of gender or MTX dose or pred-
nisolone or NSAID use. Collectively, these results
confirm findings from the microarray study and evidently
demonstrate that the regulation of IFN response gene
activity upon TNF blockade in RA is not as consistent as
previously described for SoJIA [9] and SS [11].
Change in type I interferon response gene activity is 
unrelated to baseline levels
Since the type I IFN response gene expression levels are
already highly heterogeneous in biological-naive RA
patients, we investigated whether the observed changes
were related to the magnitude of IFN response gene
expression prior to treatment. Therefore, the relationship
between the extent of the baseline IFN response gene
expression levels and its change after TNF blockade was
tested. In the 15 patients, the baseline mean expression of
the type I IFN gene set did not correlate with their corre-
sponding change after treatment (Pearson R = -0.42, P =
0.12). This was confirmed in the validation group of 18
patients by using the mean expression levels of the three
IFN response genes (RSAD2,  IFI44L, and OAS1) mea-
sured by qPCR, although a trend toward significance was
observed (Spearman R = -0.44, P = 0.064). These findings
reveal that the type I IFN response gene expression pro-
file prior to treatment is not associated with the direction
of its change upon TNF blockade.
Anti-tumor necrosis factor induced-interferon regulation 
and clinical response to treatment
Finally, we investigated whether the treatment-induced
changes in type I IFN response gene expression levels
were associated with clinical response to treatment.
Therefore, the patients (n = 15) were divided into two
groups on the basis of their change in mean expression
level for the 34 IFN response genes (ratio > 1 and ratio <
1) as demonstrated in Figure 1a. Next, clinical parameters
were compared between these two groups. Clinical
response to treatment was determined after 16 weeks of
Differential regulation of interferon (IFN) response genes upon tumor necrosis factor (TNF) blockade
Figure 1 Differential regulation of interferon (IFN) response genes upon tumor necrosis factor (TNF) blockade. The expression levels of 34 
type I IFN response genes were determined by cDNA microarray analysis in peripheral blood cells of 15 patients before (T0) and 1 month after (T1) 
anti-TNF treatment. (a) Subsequently, for each patient, the expression levels were averaged (note: data are in log2 space) and baseline levels were 
compared with post-treatment levels. The patients whose IFN response gene levels are induced after TNF blockade are indicated by red lines, and 
patients with a downregulation are indicated by green lines. Subsequently, the expression levels of three IFN response genes (RSAD2, IFI44L, and OAS1) 
were measured by quantitative real-time polymerase chain reaction (PCR) in an independent group of 18 patients. (b) The expression levels of the 
three genes were averaged, and baseline levels were compared with post-treatment levels. ns, not significant using a paired t test analysis.
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treatment. Interestingly, the patients who showed an
increase in type I IFN response gene expression levels
after 1 month of treatment had a poor clinical response to
treatment. This was reflected by less improvement in dis-
ease activity scores (P = 0.013) and higher tender joint
counts (P = 0.015) and higher Health Assessment Ques-
tionnaire-Disability Index scores (P = 0.008) after treat-
ment (Figure 2). Accordingly, all patients without an anti-
TNF-induced increase in type I IFN gene activity had a
good or moderate response to treatment as assessed by
the EULAR response criteria (P = 0.018) (Figure 2). From
a total of 29 patients, both the EULAR and the qPCR
expression data were available for the three IFN response
genes RSAD2, IFI44L, and OAS1. Analysis of the pre- ver-
sus post-treatment ration of OAS1  revealed that the
change in gene expression of OAS1 is significantly associ-
ated with clinical response to treatment (P < 0.013).
To determine whether the IFN response to TNF block-
ade was sustained over time, five EULAR good and five
EULAR poor responders were selected and the expres-
sion levels of 15 IFN response genes (selected from the
set of 34 genes used above, Table 2) were measured at
baseline and 1, 2, 3, and 4 months after treatment by
qPCR (Additional file 3). The expression levels were aver-
aged for the individual patients, and the treatment-
induced changes (ratio post- versus pre-treatment) in
Differential regulation of interferon (IFN) response genes upon tumor necrosis factor (TNF) blockade and clinical response to 
treatment
Figure 2 Differential regulation of interferon (IFN) response genes upon tumor necrosis factor (TNF) blockade and clinical response to 
treatment. Patients were divided into two groups (ratio < 1 and ratio > 1) on the basis of their IFN response upon TNF blockade and compared with 
each other with respect to clinical response to treatment. The ratio is determined by the T = 1/T = 0 expression levels of the IFN response genes as 
demonstrated in Figure 1a. Data are shown as box plots; each box represents the 25th to 75th percentiles. The lines inside represent the median, and 
the ends of the whiskers represent the smallest and largest observations. Patients with an upregulation in IFN response genes displayed a significantly 
(unpaired t test, * P < 0.05; **P < 0.01) worse clinical response to treatment as assessed by change in disease activity score (DAS) (DAS before treatment 
minus DAS 16 weeks after treatment) (a), European League Against Rheumatism (EULAR) response (b), tender joint count (TJC) (c), and Health Assess-
ment Questionnaire-Disability Index (HAQ) (d) after treatment.
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IFN response gene expression levels over time were com-
pared between the two clinical response groups using
two-way ANOVA. Overall, the IFN response genes
showed an upregulation in the poor responder group,
which was most prominent at 2 months after the start of
therapy (data not shown). At the single-gene level, the
increased expression in poor versus good responders
reached significance for the OAS1 and LGALS3BP genes
(Figure 3a, b). For three other IFN response genes (Mx2,
OAS2, and SERPING1), a trend (P = approximately 0.06,
data not shown) was observed toward increased expres-
sion in the poor responder patients. Combining these five
genes (OAS1, LGALS3BP, Mx2, OAS2, and SERPING1)
into one IFN response gene set improved the significance
(Figure 3c). These data demonstrate that poor response
to infliximab treatment is associated with treatment-
i n d u c e d  i n c r e a s e  i n  t yp e  I  I F N  r e s po n s e  g e n e  a c t i vi t y .
Discussion
I n  t h i s  s t u d y ,  w e  d e m o n s t r a t e d  t h a t  b l o c k a d e  o f  t h e
inflammatory cytokine TNF in RA patients modulates
the expression of IFN response gene activity in a hetero-
geneous manner. The data revealed that some RA
patients display a treatment-induced increased expres-
sion of type I IFN response genes whereas others display
no effect or a small decrease. We provided evidence that
the treatment-induced change in expression levels of IFN
response genes is associated with the EULAR response
rate at 16 weeks after the start of infliximab treatment.
RA patients who revealed an increased IFN response
gene expression profile after 1 to 2 months of anti-TNF
treatment exhibited a poor clinical response. No associa-
tion between clinical response to infliximab treatment
and baseline IFN response gene activity was found.
IFNs are known for their immune regulatory proper-
ties. Previously, we provided evidence for an increased
expression of type I IFN response genes in a subset of
patients with RA [13]. Upregulation of type I IFN
response genes has been reported in peripheral blood
cells of (a subset of) patients with other autoimmune dis-
eases, like SLE [1,24-26], dermatomyositis [27], and mul-
tiple sclerosis [22]. Type I IFNs (IFNαβ) exert broad dual
effects on the immune system, reflecting both immune-
stimulatory and immune-suppressive activities. Immune-
stimulatory activities relate to the activation of myeloid
dendritic cells, chemokines, chemokine receptors,
costimulatory molecules (CD40, CD80, and CD86), and
humoral responses. Immune-suppressive effects are
reflected by Th2 cell skewing and anti-proliferative and
pro-apoptotic effects. According to their dual effect on
immunity, their role in disease may range from detrimen-
tal to beneficial. Although the anti-TNF-induced increase
in IFN response activity might be an epiphenomenon
related to the effect of TNF blockade, it is tempting to
Poor response to tumor necrosis factor blockade is accompanied by upregulation of interferon (IFN) response genes
Figure 3 Poor response to tumor necrosis factor blockade is accompanied by upregulation of interferon (IFN) response genes. For five Eu-
ropean League Against Rheumatism (EULAR) (0) poor responder (red) and five EULAR (2) good responder (green) patients, the expression levels of 15 
IFN response genes were measured by quantitative real-time polymerase chain reaction (PCR) (BioMark™) at baseline and 1, 2, 3, and 4 months after 
treatment. From two poor and one good responder patients, the 3-month time points are missing. The IFN response gene expression levels during 
treatment were compared between the two clinical response groups by means of two-way analysis of variance test. Treatment-induced changes in 
the expression levels of two genes, LGALS3BP (a) and OAS1 (b), were significantly different between the two response groups. (c) The mean expression 
level of five IFN response genes (LGALS3BP, OAS1, Mx2, SERPING1, and OAS2) showed the best significant difference between the two clinical response 
groups. Graphs show the mean and standard error of the mean expression levels for each clinical response group. RQ, relative quantity.
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speculate on a role of increased IFN bioactivity in the
deteriorating clinical effects. The association between an
increase in type I IFN response gene activity and poor
response to anti-TNF treatment may suggest a harmful
role for type I IFN bioactivity in RA or, alternatively, a
failed attempt to counter-regulate inflammation.
Clinical experience revealed that a fraction of patients
treated with TNF antagonists developed (increased) anti-
dsDNA antibodies, in some cases with a concomitant
lupus-like syndrome [28,29]. From a total of 18 of the 33
patients we studied, levels of anti-citrullinated protein
antibody, rheumatoid factor, and double-stranded DNA
autoantibody, determined before and 24 weeks after TNF
blockade, were available. The expression level of IFN
response genes was not related to antibody levels at base-
line nor was the activation of the IFN response genes
related to the drug-induced formation of antibodies (data
not shown [30]).
The differences between the effects of TNF blockade
on IFN response activity between the studies in SS [11]
and SoJIA [9], on the one hand, and our studies in RA and
spondyloarthritis (SpA) [31], on the other, could have
their origin in differences in design between the studies,
such as the use of infliximab in RA versus etanercept in
SS, and the different readout systems used. For example,
the SS study was based on an indirect reporter cell assay
to measure type I IFN activity in plasma, whereas in the
SoJIA and RA studies, measurement of IFN response
gene activity in the peripheral blood cells was measured.
Using the reporter assay, we previously demonstrated
that the serum type I IFN bioactivity was increased in
SpA patients treated with etanercept whereas it was tran-
siently declined by infliximab [31]. This is suggestive for
differential effects of etanercept and infliximab on IFN
response activity, although the direct consequence for the
IFN response signature in the peripheral blood cells has
not been tested. In an attempt to find an explanation for
the apparent discrepancies in IFN response gene activity
related to clinical response to infliximab, we learned that
in both RA and SS [11,12] an increased IFN response
activity is associated with a poor clinical response.
The inter-individual differences in anti-TNF-induced
IFN response may be the result of differential regulatory
processes. Evidence that TNF blockade may exert both
inhibitory and activating effects on IFN response activity
is available. In vitro experiments suggested that endoge-
nous secretion of TNF by pDCs represents a negative
feedback on IFN production [9]. Whereas this finding
suggested that TNF displays counteracting effects on IFN
response activity, others have reported that TNF initiates
an IRF1-dependent autocrine loop leading to sustained
expression of STAT1-dependent type I IFN response
genes [32]. Hence, the divergent outcome of the IFN
response activity might be a consequence of differences
in the relative contribution of each of these processes in
the regulation of IFN response activity. Alternatively,
genetic variation in the type I IFN biology could underlie
the variation in response activity. Single-nucleotide poly-
morphisms in several transcription factors involved the
type I IFN pathway (for example, IRF5, Tyk2, and STAT4)
have recently been associated with a number of autoim-
mune diseases, including SLE [33,34] and RA [35-37].
Future studies are needed to unravel the mechanism
behind the divergent alterations in IFN response gene
activity upon TNF blockade. Since the current informa-
tion on the differential IFN response gene activity does
not have predictive value to identify responders before
the start of therapy, detailed insight in the regulatory pro-
cesses that underlie this effect might be helpful to identify
such biomarkers. Therefore, in vitro studies with blood
cells that are treated with a TNF blocker might be useful.
Conclusions
In summary, this study shows that there is a large varia-
tion between RA patients in the change of IFN response
gene expression levels during TNF blockade. The change
in IFN response genes is unrelated to baseline expression
levels. Interestingly, treatment-induced increase of IFN
response gene activity is associated with poor clinical
response to infliximab treatment. Additional studies in
larger patient cohorts should reproduce and confirm
these findings.
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